Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir

Q: How long will it take to read this news story?

The story "Dr Reddy&#039;s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir" has 480 words across 19 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Dr Reddy&#039;s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir" was covered 7 hours ago by Times of India, a news publisher based in India.

Q: How trustworthy is 'Times of India' news outlet?

Times of India is a fully independent (privately-owned) news outlet established in 1838 that covers mostly economy and business news. The outlet is headquartered in India and publishes an average of 19 news stories per day. It's most recent story was published 46 minutes ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22852898</li><li>URL: https://beamstart.com/news/dr-reddys-hetero-ink-royalty-17278966714145</li></ul>

Times of India 7h ago

Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir - Times of India

Quick Summary:

Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs.

Lenacapavir, which inhibits HIV at multiple stages, recently showed promising results in prevention trials.

Earlier this month, Gilead announced promising results from a pivotal Phase-3 clinical trial that showed Lenacapavir reduced HIV infections by 96% compared to the background HIV incidence.